Description

Urinary tract infections (UTIs) are common infections that happen when bacteria, often from the skin or rectum, enter the urethra, and infect the urinary tract. They usually occur in the bladder or urethra, but more serious infections involve the kidney. A bladder infection may cause pelvic pain, increased urge to urinate, pain with urination, and blood in the urine. A kidney infection may cause back pain, nausea, vomiting, and fever. According to a report by StrategyHelix, the global urinary tract infection market is set to increase by US$ 2,011.4 million during 2022-2028, growing at a CAGR of 3.5% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for urinary tract infection. The global urinary tract infection market is segmented on the basis of drug class, application, pathogen, end user, and region. On the basis of drug class, the global urinary tract infection market has been segmented into aminoglycosides, azoles, beta-lactam & cephalosporins, penicillin, quinolones, others. The quinolones segment is estimated to account for the largest share of the global urinary tract infection market. By application, the global urinary tract infection market has been segmented into cystitis, pyelonephritis, urethritis, others. The urethritis segment held the largest revenue share in 2021. Based on pathogen, the global urinary tract infection market is categorized into Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus saprophyticus, others. On the basis of end user, the global urinary tract infection market has been segmented into clinics, hospitals, self administered, others. Geographically, the global urinary tract infection market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global urinary tract infection market is highly competitive. The report also includes the profiles of leading companies such as Allergan plc, Bayer AG, Cipla Limited, Eli Lily Company, GSK plc, Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the urinary tract infection market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Drug class: aminoglycosides, azoles, beta-lactam & cephalosporins, penicillin, quinolones, others
Application: cystitis, pyelonephritis, urethritis, others
Pathogen: Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus saprophyticus, others
End user: clinics, hospitals, self administered, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global urinary tract infection market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Urinary tract infection market overview
Part 3. Market breakdown by drug class
– Aminoglycosides
– Azoles
– Beta-lactam & cephalosporins
– Penicillin
– Quinolones
– Others
Part 4. Market breakdown by application
– Cystitis
– Pyelonephritis
– Urethritis
– Others
Part 5. Market breakdown by pathogen
– Enterococcus faecalis
– Escherichia coli
– Klebsiella pneumoniae
– Proteus mirabilis
– Staphylococcus saprophyticus
– Others
Part 6. Market breakdown by end user
– Clinics
– Hospitals
– Self administered
– Others
Part 7. Market breakdown by region
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)
Part 8. Key companies
– Allergan plc
– Bayer AG
– Cipla Limited
– Eli Lily Company
– GSK plc
– Merck & Co. Inc.
– Novartis AG
– Novo Nordisk A/S
– Pfizer Inc.
– Teva Pharmaceutical Industries Ltd.
About StrategyHelix
Disclaimer